Moreover, the proportions of IDH1 and TERT promoter mutations were higher in neocortical gliomas than in mesocortical gliomas (67.9% vs. 31.6%, p < 0.01 and 68.4% vs. 25.0%, p < 0.001, respectively). Here, IDH1 is linked to central nervous system cancer.